The findings, published in Clinical Cancer Research, emphasize Versamune® HPV's potential ahead of a planned Phase 3 trial for HPV16-positive head and neck squamous cell carcinoma (HNSCC ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results ...

However, if a woman is found to be HPV positive with a high-risk strand (HPV 16 and/or 18), also referred to as a high-grade lesion, she will then be sent for further testing right away.

Individuals testing positive for human papillomavirus (HPV) had a 40% greater risk for overall cardiovascular disease (CVD) ...

In addition to causing several types of cancer, human papillomavirus (HPV) appears to bring a significantly increased risk of ...

VERSATILE-003 is a global, multi-center, randomized, controlled and open-label Phase 3 pivotal trial designed to evaluate the safety and efficacy of Versamune ® HPV in combination with ...

However, a positive HPV test does not indicate malignancy ... Cervarix targets the two most common high-risk strains, HPV 16 ...

Research presented at the American College of Cardiology has found that individuals positive for human papillomavirus (HPV) face a 40% higher risk of heart disease compared to HPV-negative individuals ...

PRINCETON, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...